Portage Biotech IncNASDAQ:PRTG
- LAST PRICE4.0900
- TODAY'S CHANGE (%)0.1400 (3.5443%)
- Bid / Lots3.9100/ 2
- Ask / Lots4.3100/ 7
- Open / Previous Close4.1400 / 3.9500
- Day Range
- 52 Week Range
- Volume23,699
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PRTG |
|---|---|---|
| 09:53 ET | 650 | 4.14 |
| 10:04 ET | 200 | 4.41 |
| 10:27 ET | 438 | 3.97 |
| 10:36 ET | 100 | 4.3 |
| 11:12 ET | 108 | 4.1454 |
| 11:41 ET | 800 | 4.15 |
| 11:50 ET | 365 | 4.01 |
| 12:30 ET | 100 | 4.091 |
| 02:07 ET | 211 | 4.0601 |
| 02:14 ET | 100 | 4.0052 |
| 02:43 ET | 100 | 4.04 |
| 03:19 ET | 222 | 4.06 |
| 03:39 ET | 100 | 4.1 |
| 03:51 ET | 350 | 4.0988 |
| 04:00 ET | 3178 | 4.09 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Portage Biotech Inc | 4.3M | -0.1x | --- |
Pasithea Therapeutics Corp | 4.3M | -0.2x | --- |
NuCana PLC | 3.4M | 0.0x | --- |
Protagenic Therapeutics Inc | 4.2M | -0.4x | --- |
Galmed Pharmaceuticals Ltd | 4.4M | -0.1x | --- |
Windtree Therapeutics Inc | 4.2M | -0.6x | --- |
Company Information
Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is engaged in advancing therapies to improve long-term treatment response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of four platforms, with lead programs consisting of invariant natural killer T-cell (iNKT) engagers and a suite of treatments targeting the adenosine pathway. Within these four platforms, the Company has nine product candidates, of which five are pre-clinical and four of which are clinical stage. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent targeting the adenosine pathway.
Contact Information
- Headquarters
- Clarence Thomas Building, Road Town P.O. Box 4649TORTOLA, ON, Virgin Islands (British) VG1110
- Phone
- 416-929-1806
- Fax
- 416-929-6612
Executives
- Chairman of the Board, Chief Executive Officer
- Ian Walters
- Chief Financial Officer, Secretary
- Allan Shaw
- Chief Scientific Officer
- Robert Kramer
- Vice President - Project Management and Operations
- Steven Innaimo
- Vice President - Development
- Justin Fairchild
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-68.81 |
Book Value | $4.07 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
